SUMOylation regulates AKT1 activity

Oncogene

Volumn 34, Issue 11, 2015, Pages 1442-1450

  De La Cruz Herrera, C F ^a   Campagna, M ^a   Lang, V ^b   Del Carmen Gonzalez Santamaria J ^a   Marcos Villar, L ^a   Rodriguez M S ^b   Vidal, A ^c   Collado, M ^d   Rivas, C ^a,e  

^a CENTRO NACIONAL DE BIOTECNOLOGÍA   (Spain)

^b Inbiomed   (Spain)

^c UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^d Santiago University Clinical Hospital   (Spain)

^e NONE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AKT1 PROTEIN, HUMAN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SUMO 1 PROTEIN; SUMO PROTEIN; SUMO1 PROTEIN, HUMAN; SUMO2 PROTEIN, HUMAN; SUMO3 PROTEIN, HUMAN; UBIQUITIN;

3T3 CELL LINE; ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; CELL PROLIFERATION; CHLOROCEBUS AETHIOPS; COS 1 CELL LINE; ENZYME ACTIVATION; FEMALE; GENETICS; HEK293 CELL LINE; HELA CELL LINE; HUMAN; MCF 7 CELL LINE; METABOLISM; MOUSE; MUTATION; NEOPLASM; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; SIGNAL TRANSDUCTION; SUMOYLATION; TUMOR CELL LINE;

3T3 CELLS; ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CERCOPITHECUS AETHIOPS; COS CELLS; ENZYME ACTIVATION; FEMALE; HEK293 CELLS; HELA CELLS; HUMANS; MCF-7 CELLS; MICE; MUTATION; NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; SMALL UBIQUITIN-RELATED MODIFIER PROTEINS; SUMO-1 PROTEIN; SUMOYLATION; UBIQUITINS;

EID: 84897355918     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2014.48     Document Type: Article

References (36)

1. Testa JR, Tsichlis PN. AKT signaling in normal and malignant cells. Oncogene 2005; 24: 7391-7393.
2. Alessi DR, Cohen P. Mechanism of activation and function of protein kinase B. Curr Opin Genet Dev 1998; 8: 55-62.
3. Calleja V, Laguerre M, Larijani B. 3-D structure and dynamics of protein kinase B-new mechanism for the allosteric regulation of an AGC kinase. J Chem Biol 2009; 2: 11-25.
4. Brodbeck D, Cron P, Hemmings BA. A human protein kinase Bgamma with regulatory phosphorylation sites in the activation loop and in the C-terminal hydrophobic domain. J Biol Chem 1999; 274: 9133-9136.
5. Flotho A, Melchior F. Sumoylation: a regulatory protein modification in health and disease. Annu Rev Biochem 2013; 82: 357-385.
6. Hay RT. SUMO: a history of modification. Mol Cell 2005; 18: 1-12.
7. Gonzalez-Santamaria J, Campagna M, Ortega-Molina A, Marcos-Villar L, de la Cruz-Herrera CF, Gonzalez D et al. Regulation of the tumor suppressor PTEN by SUMO. Cell Death Dis 2012; 3: e393.
8. Golebiowski F, Matic I, Tatham MH, Cole C, Yin Y, Nakamura A et al. System-wide changes to SUMO modifications in response to heat shock. Sci Signal 2009; 2: ra24.
9. Hietakangas V, Ahlskog JK, Jakobsson AM, Hellesuo M, Sahlberg NM, Holmberg CI et al. Phosphorylation of serine 303 is a prerequisite for the stress-inducible SUMO modification of heat shock factor 1. Mol Cell Biol 2003; 23: 2953-2968.
10. Hong Y, Rogers R, Matunis MJ, Mayhew CN, Goodson ML, Park-Sarge OK et al. Regulation of heat shock transcription factor 1 by stress-induced SUMO-1 modification. J Biol Chem 2001; 276: 40263-40267.
11. Mao Y, Desai SD, Liu LF. SUMO-1 conjugation to human DNA topoisomerase II isozymes. J Biol Chem 2000; 275: 26066-26073.
12. Miller MJ, Scalf M, Rytz TC, Hubler SL, Smith LM, Vierstra RD. Quantitative proteomics reveals factors regulating RNA biology as dynamic targets of stress-induced SUMOylation in Arabidopsis. Mol Cell Proteomics 2013; 12: 449-463.
13. Tatham MH, Matic I, Mann M, Hay RT. Comparative proteomic analysis identifies a role for SUMO in protein quality control. Sci Signal 2011; 4: rs4.
14. Trotman LC, Alimonti A, Scaglioni PP, Koutcher JA, Cordon-Cardo C, Pandol fi PP. Identification of a tumour suppressor network opposing nuclear Akt function. Nature 2006; 441: 523-527.
15. Kulik G, Klippel A, Weber MJ. Antiapoptotic signalling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase, and Akt. Mol Cell Biol 1997; 17: 1595-1606.
16. Liu X, Powlas J, Shi Y, Oleksijew AX, Shoemaker AR, De Jong R et al. Rapamycin inhibits Akt-mediated oncogenic transformation and tumor growth. Anticancer Res 2004; 24: 2697-2704.
17. Sakoda H, Gotoh Y, Katagiri H, Kurokawa M, Ono H, Onishi Y et al. Differing roles of Akt and serum- and glucocorticoid-regulated kinase in glucose metabolism, DNA synthesis, and oncogenic activity. J Biol Chem 2003; 278: 25802-25807.
18. Sun M, Wang G, Paciga JE, Feldman RI, Yuan ZQ, Ma XL et al. AKT1/PKBalpha kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells. Am J Pathol 2001; 159: 431-437.
19. Bang OS, Ha BG, Park EK, Kang SS. Activation of Akt is induced by heat shock and involved in suppression of heat-shock-induced apoptosis of NIH3T3 cells. Biochem Biophys Res Commun 2000; 278: 306-311.
20. Yoshihara T, Naito H, Kakigi R, Ichinoseki-Sekine N, Ogura Y, Sugiura T et al. Heat stress activates the Akt/mTOR signalling pathway in rat skeletal muscle. Acta Physiol (Oxf) 2013; 207: 416-426.
21. Sato S, Fujita N, Tsuruo T. Modulation of Akt kinase activity by binding to Hsp90. Proc Natl Acad Sci USA 2000; 97: 10832-10837.
22. Warfel NA, Niederst M, Newton AC. Disruption of the interface between the pleckstrin homology (PH) and kinase domains of Akt protein is sufficient for hydrophobic motif site phosphorylation in the absence of mTORC2. J Biol Chem 2011; 286: 39122-39129.
23. Laine J, Kunstle G, Obata T, Sha M, Noguchi M. The protooncogene TCL1 is an Akt kinase coactivator. Mol Cell 2000; 6: 395-407.
24. Steinacher R, Schar P. Functionality of human thymine DNA glycosylase requires SUMO-regulated changes in protein conformation. Curr Biol 2005; 15: 616-623.
25. Johnson ES. Protein modification by SUMO. Annu Rev Biochem 2004; 73: 355-382.
26. Bossis G, Melchior F. SUMO: regulating the regulator. Cell Div 2006; 1: 13.
27. Lallemand-Breitenbach V, Jeanne M, Benhenda S, Nasr R, Lei M, Peres L et al. Arsenic degrades PML or PML-RARalpha through a SUMO-triggered RNF4/ubiquitin-mediated pathway. Nat Cell Biol 2008; 10: 547-555.
28. Matic I, van Hagen M, Schimmel J, Macek B, Ogg SC, Tatham MH et al. In vivo identification of human small ubiquitin-like modifier polymerization sites by high accuracy mass spectrometry and an in vitro to in vivo strategy. Mol Cell Proteomics 2008; 7: 132-144.
29. Bawa-Khalfe T, Yeh ET. SUMO Losing Balance: SUMO Proteases Disrupt SUMO Homeostasis to Facilitate Cancer Development and Progression. Genes Cancer 2010; 1: 748-752.
30. Hsieh AC, Bo R, Manola J, Vazquez F, Bare O, Khvorova A et al. A library of siRNA duplexes targeting the phosphoinositide 3-kinase pathway: determinants of gene silencing for use in cell-based screens. Nucleic Acids Res 2004; 32: 893-901.
31. Ramaswamy S, Nakamura N, Vazquez F, Batt DB, Perera S, Roberts TM et al. Regulation of G1 progression by the PTEN tumor suppressor protein is linked to inhibition of the phosphatidylinositol 3-kinase/Akt pathway. Proc Natl Acad Sci USA 1999; 96: 2110-2115.
32. Desterro JM, Rodriguez MS, Hay RT. SUMO-1 modification of IkappaBalpha inhibits NF-kappaB activation. Mol Cell 1998; 2: 233-239.
33. Vertegaal AC, Andersen JS, Ogg SC, Hay RT, Mann M, Lamond AI. Distinct and overlapping sets of SUMO-1 and SUMO-2 target proteins revealed by quantitative proteomics. Mol Cell Proteomics 2006; 5: 2298-2310.
34. Nguyen H, Gitig DM, Koff A. Cell-free degradation of p27(kip1), a G1 cyclin-dependent kinase inhibitor, is dependent on CDK2 activity and the proteasome. Mol Cell Biol 1999; 19: 1190-1201.
35. Campagna M, Herranz D, Garcia MA, Marcos-Villar L, Gonzalez-Santamaria J, Gallego P et al. SIRT1 stabilizes PML promoting its sumoylation. Cell Death Differ 2011; 18: 72-79.
36. Marcos-Villar L, Lopitz-Otsoa F, Gallego P, Munoz-Fontela C, Gonzalez-Santamaria J, Campagna M et al. Kaposi's sarcoma-associated herpesvirus protein LANA2 disrupts PML oncogenic domains and inhibits PML-mediated transcriptional repression of the survivin gene. J Virol 2009; 83: 8849-8858.